Laurent Lavigne du Cadet
Director Financiero/CFO en NeuroCytonix, Inc. .
Cargos activos de Laurent Lavigne du Cadet
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
NeuroCytonix, Inc.
 NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | Director de Operaciones | - | - |
| Director Financiero/CFO | - | - |
Historial de carrera de Laurent Lavigne du Cadet
Estadísticas
Internacional
| Estados Unidos | 2 |
Operativa
| Chief Operating Officer | 1 |
| Director of Finance/CFO | 1 |
Sectorial
| Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
NeuroCytonix, Inc.
NeuroCytonix, Inc. BiotechnologyHealth Technology NeuroCytonix, Inc. is an emerging biotechnology company based in Rockville, MD. Dr. J. Roberto Trujillo, an MD and PhD from Harvard University, has been a leader in clinical and basic neuroscience research for brain regeneration technology for the past 25 years. NeuroCytonix develops and exploits transformational medical technologies for the regeneration of the nervous system. The company's core technology, the NeuroCytoTron, utilizes non-invasive, safe, tissue engineering technology that stimulates proteins aiding in the regeneration of brain cells. The company's technology and related protocols include stroke, autism, cerebral palsy, and neurological consequences of traumatic brain injury (TBI) and COVID-19. The company was founded in 2017 by J. Roberto Trujillo, who is also the CEO. | Health Technology |
